Federal award (DELIVERY ORDER, fiscal year 2022)
Recipient: THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-09-15 to 2025-03-14
Current total value of award: $1097981
Description: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINTS BIOMARKERS  TASK ORDER TITLE: TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE